Ziprasidone hydrochloride

CAS No. 122883-93-6

Ziprasidone hydrochloride( CP88059 hydrochloride | CP 88059 hydrochloride )

Catalog No. M10892 CAS No. 122883-93-6

A full antagonist of D2 and 5-HT2A receptors with Ki of 6.8 and 0.6 nM, respectively; also is a partial agonist of 5-HT1A, and a partial antagonist of 5-HT2C and 5-HT1D receptors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 42 In Stock
5MG 35 In Stock
10MG 48 In Stock
25MG 81 In Stock
50MG 126 In Stock
100MG 157 In Stock
200MG Get Quote In Stock
500MG 389 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ziprasidone hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    A full antagonist of D2 and 5-HT2A receptors with Ki of 6.8 and 0.6 nM, respectively; also is a partial agonist of 5-HT1A, and a partial antagonist of 5-HT2C and 5-HT1D receptors.
  • Description
    A full antagonist of D2 and 5-HT2A receptors with Ki of 6.8 and 0.6 nM, respectively; also is a partial agonist of 5-HT1A, and a partial antagonist of 5-HT2C and 5-HT1D receptors; exhibits potent antipsychotic activity in vivo.Schizophrenia Approved(In Vitro):Ziprasidone hydrochloride (0-500 nM, 150 seconds) blocks wild-type hERG current.(In Vivo):Ziprasidone hydrochloride (oral gavage; 20 mg/kg; once daily; 7 weeks) results in weight loss, low level physical activity, high resting energy expenditure and greater capacity for thermogenesis when subjected to cold.
  • In Vitro
    Ziprasidone hydrochloride (0-500 nM, 150 seconds) blocks wild-type hERG current. Cell Viability Assay Cell Line:HEK-293 cells Concentration:0-500 nM Incubation Time:150 seconds Result:Blocked wild-type hERG current in a voltage- and concentration-dependent manner (IC50 = 120 nm).
  • In Vivo
    Ziprasidone hydrochloride (oral gavage; 20 mg/kg; once daily; 7 weeks) results in weight loss, low level physical activity, high resting energy expenditure and greater capacity for thermogenesis when subjected to cold. Animal Model:Eight-week-old female Sprague-Dawleyrats weighing 200 to 250 g Dosage:20 mg/kg Administration:Oral gavage; 20 mg/kg; once daily; 7 weeks Result:Gained significantly less weight (P = 0.031), had a lower level of physical activity (P = 0.016), showed a higher resting energy expenditure (P < 0.001), and displayed a greater capacity for thermogenesis when subjected to cold (P < 0.001).
  • Synonyms
    CP88059 hydrochloride | CP 88059 hydrochloride
  • Pathway
    GPCR/G Protein
  • Target
    5-HT Receptor
  • Recptor
    5-HTtransporter|5-HT1A|5-HT1B|5-HT1D|5-HT2A|5-HT2C|5-HT6|5-HT7|D1|D2|D3|H1receptor|norepinephrinetransporter(NET)|α1A-adrenergicreceptor|α2A-adrenergicreceptor
  • Research Area
    Neurological Disease
  • Indication
    Schizophrenia

Chemical Information

  • CAS Number
    122883-93-6
  • Formula Weight
    449.3966
  • Molecular Formula
    C21H22Cl2N4OS
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    Cl.ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
  • Chemical Name
    2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, hydrochloride (1:1)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Mattei C, et al. J Cent Nerv Syst Dis. 2011 Feb 15;3:1-16. 2. Seeger TF, et al. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13. 3. Schotte A, et al. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
molnova catalog
related products
  • Adatanserin hydrochl...

    Adatanserin hydrochloride (WY50324 hydrochloride) is a novel 5-HT(1A)/5-HT(2) receptor ligand with potential neuroprotective effects and inhibition of ischemic efflux of endogenous amino acids, which can be used in the study of depression and anxiety disorders.

  • Alosetron

    A potent and selective 5-HT3 receptor antagonist has been shown to be beneficial in the treatment of irritable bowel syndrome.

  • 5-HT2 antagonist 1

    5-HT2 antagonist 1 is a potent 5-HT2 receptor antagonist with weak α1 adrenoceptor blocking activity.